News Author: Susan London Publish date: February 11, 2016
Key clinical point: The ADT resistance signature may help identify men who are unlikely to benefit from adjuvant ADT.
Major finding: Among men giv...
News Author: Susan London Publish date: February 4, 2016
Key clinical point: Tumor ERCC1 expression does not appear helpful for selecting a first-line regimen for colorectal cancer.
Major finding: Among ...
News Author: Susan London Publish date: February 1, 2016
Key clinical point: Patients with rectal cancer who receive radiation therapy have a lower risk of second pelvic tumors.
Major finding: Compared w...
News Author: Susan London Publish date: January 31, 2016
Receiving adjuvant therapy for pancreatic cancer at a center that treats a high volume of patients with the disease confers a survival advantage, acco...
News Author: Susan London Publish date: January 29, 2016
Blockade of the cell surface receptor programmed death–1 (PD-1) is highly efficacious in patients with advanced noncolorectal cancers of the gastroint...
News Author: Susan London Publish date: January 28, 2016
Key clinical point: Nivolumab and pembrolizumab appear active and well tolerated in patients with previously treated esophagogastric cancers. Major...
News Author: Susan London Publish date: January 21, 2016
Key clinical point: A regimen of short-course radiation followed by chemotherapy offers a new treatment option for patients with locally advanced ...
News Author: Susan London Publish date: January 20, 2016
Key clinical point: Everolimus reduces the risk of progression or death across subgroups of patients who have advanced, progressive neuroendocrine...
News Author: Susan London Publish date: January 20, 2016
Key clinical point: 177Lu-Dotatate appears efficacious and safe for the treatment of advanced midgut neuroendocrine tumors.
Major finding: Median ...
News Author: Susan London Publish date: January 19, 2016
Key clinical point: Hypofractionated radiation therapy was not inferior to conventional radiation therapy in men with low-risk or predominantly in...
News Author: Susan London Publish date: January 19, 2016
Key clinical point: The longer men lived without any recurrence, the greater their probability of remaining alive and disease free in the future.
...
News Author: Susan London Publish date: January 15, 2016
Key clinical point: The poorer survival of African American patients vs.
News Author: Susan London Publish date: January 14, 2016
Key clinical point: Adding celecoxib and zoledronic acid to standard of care improves outcomes in men with metastatic hormone-naive prostate cance...
News Author: Susan London Publish date: January 13, 2016
Key clinical point: Atezolizumab is active in advanced urothelial cancer, especially in patients whose immune cells have higher expression of PD-L...
News Author: Susan London Publish date: January 12, 2016
Key clinical point: Nivolumab was superior to everolimus regardless of disease characteristics and prior therapies.
Major finding: All subgroups h...
